MedTrace Logo

Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure

NCT06578520 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2025-08-06

No results posted yet for this study

Summary

Cross-over, 2-sequence, 2-treatment, 2-period single-centre, phase IV, randomized, open label study.

Conditions

Interventions

DRUG

Dapagliflozin

10 mg once per day, oral tablets

Sponsors & Collaborators

  • Fundación para la Investigación del Hospital Clínico de Valencia

    lead OTHER

Principal Investigators

  • Marco Montomoli · Hospital Clínico Universitario de Valencia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-07-30
Primary Completion
2025-12-01
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06578520 on ClinicalTrials.gov